|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123396 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-26 20:04:53 |
|
注册时间: Date of Registration: |
2026-04-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
智能温控柔性输尿管镜联合铥光纤激光治疗 2-4cm 肾结石的随机对照试验 |
|
Public title: |
A randomized controlled trial of intelligent temperature-controlled flexible ureteroscopy combined with thulium fiber laser for the treatment of 2–4 cm kidney stones |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
智能温控柔性输尿管镜联合铥光纤激光治疗 2-4cm 肾结石的随机对照试验 |
|
Scientific title: |
A randomized controlled trial of intelligent temperature-controlled flexible ureteroscopy combined with thulium fiber laser for the treatment of 2–4 cm kidney stones |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张鹤 |
研究负责人: |
张鹤 |
|
Applicant: |
He Zhang |
Study leader: |
He Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 136 6197 8648 |
研究负责人电话: Study leader's telephone: |
+86 136 6197 8648 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xyxtpwy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xyxtpwy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区苗圃路219号 |
研究负责人通讯地址: |
上海市浦东新区苗圃路219号 |
|
Applicant address: |
No. 219, Miaopu Road, Pudong New Area, Shanghai |
Study leader's address: |
No. 219, Miaopu Road, Pudong New Area, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海健康医学院附属浦东公利医院 |
||
|
Applicant's institution: |
Pudong Gongli Hospital,Shanghai University of Medicine & Health Sciences |
||
|
研究负责人所在单位: |
上海健康医学院附属浦东公利医院 |
||
|
Affiliation of the Leader: |
Pudong Gongli Hospital,Shanghai University of Medicine & Health Sciences |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
GLYY1s2026-048 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市浦东新区公利医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of Gongli Hospital, Pudong New Area, Shanghai |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-27 00:00:00 |
||
|
伦理委员会联系人: |
邓生琼 |
||
|
Contact Name of the ethic committee: |
Shengqiong Deng |
||
|
伦理委员会联系地址: |
上海市浦东新区苗圃路219号 |
||
|
Contact Address of the ethic committee: |
No. 219, Miaopu Road, Pudong New Area, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 5885 8730 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海健康医学院附属浦东公利医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Pudong Gongli Hospital,Shanghai University of Medicine & Health Sciences |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市浦东新区苗圃路219号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 219, Miaopu Road, Pudong New Area, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
浦东新区卫生健康委员会学科带头人培养项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Pudong New Area Health Commission Discipline Leader Training Program |
||||||||||||||||||||||
|
Target disease: |
Renal calculi |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在评价智能可控温控压输尿管软镜联合铥光纤激光碎石术治疗2~4 cm肾输尿管结石的安全性、有效性及社会经济学价值,为临床手术方式的选择提供高质量循证医学证据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to evaluate the safety, efficacy and economic value of the combined use of intelligent controllable temperature-controlled pressure flexible ureteroscopy and thulium fiber laser lithotripsy in the treatment of 2-4 cm renal and ureteral calculi, and to provide high-quality evidence-based medical evidence for the selection of clinical surgical methods. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.18 - 70 岁,性别不限; 2.计算机断层扫描(computed tomograpy,CT)测得结石最大直径在2-4cm或结石最大径之和为 2 - 4cm; 3.术前无感染或感染已控制,尿培养阴性。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age range: 18 - 70 years old, gender not restricted; 2. The maximum diameter of the stone measured by computed tomography (CT) is between 2 - 4 cm, or the sum of the maximum diameters of the stones is 2 - 4 cm; 3. There was no infection before the operation or the infection has been controlled, and the urine culture was negative. |
||||||||||||||||||||||
|
排除标准: |
1.18 - 70 周岁以外患者和孕妇; 2.肾内感染者和马蹄肾、肾移植患者; 3.无法停止的抗凝药物应用、有出血倾向、严重心肺功能不全、严重脊柱或髋关节畸形的患者、泌尿系统解剖异常而无法接受内窥镜手术的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients over 70 years old and pregnant women; 2. Patients with internal kidney infections and those with horseshoe kidneys, kidney transplants; 3. Patients who cannot stop using anticoagulant drugs, have a bleeding tendency, severe cardiac or pulmonary dysfunction, severe spinal or hip deformities, or have anatomical abnormalities in the urinary system that prevent them from undergoing endoscopic surgery. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-03-27 00:00:00至 To 2026-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-04-26 00:00:00 至 To 2026-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用区组随机化,使用 SAS 9.4 软件生成随机数字序列,通过手机应用程序(APP)完成随机分组。实验组与对照组按 1:1 比例分配。本研究为开放标签(open-label)设计,研究者与受试者均知晓分组情况,但采用随机分配隐藏:当研究人员确认受试者符合入组条件后,将基本信息输入随机系统,系统记录后即通知研究人员该受试者的组别分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using block randomization, a random number sequence was generated using SAS 9.4 software, and randomization was completed through a mobile application (APP). The experimental group and the control group were allocated in a 1:1 ratio. This study is an open-label design, in which both investigators and participants are aware of the group assignments. However, allocation concealment was implemented: after the investigator confirms that the subject meets the inclusion criteria, the basic information is entered into the randomization system. Once the system records the information, it notifies the investigator of the subject's group assignment. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |